Mirum Pharmaceuticals Inc (MIRM): Next-Year EPS Estimate 95.63%
As of 2026-06-04, Mirum Pharmaceuticals Inc (MIRM) has a next-year EPS growth estimate of 95.63%.
On 2026-06-03, analyst consensus for MIRM's next-year EPS growth shifted from 96.13% to 95.63% — a negative change of 0.50 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at -3230.13%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 95.63%
- EPS growth this year
- -3230.13%
- EPS next quarter (est)
- -$0.74
- Last price
- $92.49
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 95.63% | -3230.13% | -$0.74 | $92.49 |
| 2026-06-03 | 95.63% | -3230.13% | -$0.74 | $91.83 |
| 2026-06-02 | 96.13% | -3196.76% | -$0.76 | $92.17 |
| 2026-06-01 | 96.13% | -3196.82% | -$0.76 | $96.33 |
| 2026-05-31 | 96.13% | -3196.89% | -$0.76 | $101.50 |
| 2026-05-28 | 96.13% | -3196.89% | -$0.76 | $99.60 |
| 2026-05-27 | 96.13% | -3196.89% | -$0.76 | $97.33 |
| 2026-05-26 | 96.13% | -3196.89% | -$0.76 | $98.90 |
| 2026-05-25 | 96.13% | -3196.89% | -$0.76 | $98.62 |
| 2026-05-24 | 96.13% | -3196.89% | -$0.76 | $98.62 |
| 2026-05-21 | 96.13% | -3196.89% | -$0.76 | $100.67 |
| 2026-05-20 | 96.13% | -3196.89% | -$0.76 | $96.95 |
| 2026-05-19 | 96.17% | -3219.15% | -$0.78 | $95.65 |
| 2026-05-18 | 98.11% | -3177.95% | -$0.77 | $95.49 |
| 2026-05-17 | 98.11% | -3177.95% | -$0.77 | $102.18 |
| 2026-05-14 | 98.11% | -3177.95% | -$0.77 | $111.39 |
| 2026-05-13 | 98.03% | -3192.46% | -$0.78 | $110.28 |
| 2026-05-12 | 98.03% | -3192.46% | -$0.78 | $106.88 |
| 2026-05-11 | 98.03% | -3192.46% | -$0.78 | $106.17 |
| 2026-05-10 | 98.03% | -3192.46% | -$0.78 | $107.16 |
| 2026-05-07 | 98.03% | -3192.46% | -$0.78 | $102.93 |
| 2026-05-06 | 92.59% | -273.13% | -$0.37 | $110.08 |
| 2026-05-05 | 92.59% | -273.13% | -$0.37 | $105.81 |
| 2026-05-04 | 100.31% | -269.09% | -$0.37 | $105.79 |
| 2026-05-03 | 101.59% | -264.41% | -$0.37 | $96.53 |
| 2026-04-30 | 101.59% | -264.41% | -$0.37 | $97.31 |
| 2026-04-29 | 101.59% | -264.41% | -$0.37 | $94.20 |
| 2026-04-28 | 101.63% | -268.03% | -$0.37 | $94.00 |
| 2026-04-27 | 101.63% | -268.03% | -$0.37 | $92.48 |
| 2026-04-26 | 96.60% | -293.76% | -$0.39 | $91.49 |
Recent News
- The $1 Billion-Plus Opportunity That Sent Mirum Pharma Catapulting To A RecordInvestor's Business Daily
- Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing CholangitisBusiness Wire
- Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026Business Wire
- Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta VirusBusiness Wire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Mirum Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Mirum Pharmaceuticals Inc (MIRM) has a next-year EPS growth estimate of 95.63%, based on analyst consensus.
When was the latest EPS estimate revision for MIRM?▾
The most recent revision occurred on 2026-06-03, when analysts adjusted the next-year EPS growth estimate from 96.13% to 95.63%.
What sector and industry does Mirum Pharmaceuticals Inc belong to?▾
Mirum Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. MIRM appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Mirum Pharmaceuticals Inc (MIRM) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports